Ashley Pournamdari

evERA Breast Cancer: The ESR1 Story After CDK4/6 Failure Part 1 — Why evERA? After progression on CDK4/6 inhibitor + endocrine therapy, resistance may be driven by ESR1 mutation and PI3K–AKT–mTOR signaling. evERA tested giredestrant + everolimus vs standard ET + everolimus. Part 2 — Did it work? ESR1-mutated: PFS 10.0 vs 5.5 mo; HR 0.38 Overall population: PFS 8.8 vs 5.5 mo; HR 0.56 ESR1 not detected: PFS 5.7 vs 5.5 mo; HR 0.84 → no clear PFS advantage. The KM curves tell the story: the strongest and most sustained separation is in ESR1-mutated disease. OS shows an encouraging but still immature signal: HR 0.62 in ESR1-mutated disease and 0.69 overall. Part 3 — Take-home Safety was broadly expected. A key limitation is ESR1 enrichment (55.5%), so the overall-population result should not be assumed to apply equally to all patients. Take-home: evERA is primarily an ESR1-mutated combination story — stronger ER blockade + mTOR blockade produced the clearest PFS benefit. Reference: Mayer EL, Tolaney SM, Martín M, et al. N Engl J Med. 2026;395:1285–1298. doi:10.1056/NEJMoa2602457. #evERA #ESR1 #Giredestrant #Everolimus #BreastCancer #CDK46 #MedicalOncology #MVOnco